KU Hematology & Medical Oncology Review 2019

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

KU Hematology & Medical Oncology Review 2019

Lung
Hematologic Malignancies
Gastrointestinal
Head and Neck
Genitourinary
Skin
Palliative
General

KU ASCO 2019 Update on Recent Developments in AML - CX-01, HuF59 Anti-CD47 Antibody, Ivosidenib + Azacitidine

By KU Hematology & Medical Oncology Review 2019 FEATURING Tara Lin

193 views

August 19, 2019

Comments 0

Treatment Decisions When Initiating a Tyrosine Kinase Inhibitor and …

Feat. K. Hanna, J. Strauss

Hypothetical Patient Case: 1L Advanced Renal Cell Carcinoma With Mul…

Feat. R. Alter, A. Rezazadeh

Hematologic Malignancies

KU ASCO 2019 Hairy Cell Leukemia Highlights - Moxetumomab Pasudotox …

KU Hematology & Medical Oncology Review 2019

A. Yacoub

60 views

KU ASCO 2019 CML Updates - Criteria for Treatment Discontinuation & …

KU Hematology & Medical Oncology Review 2019

A. Yacoub

163 views

KU ASCO 2019 MDS & MPN Update - Luspatercept in Lower-Risk MDS & Rux…

KU Hematology & Medical Oncology Review 2019

A. Yacoub

91 views

KU ASCO 2019 Targeted Therapy Drugs for AML - CPX-351, FLT3, IDH Inh…

KU Hematology & Medical Oncology Review 2019

T. Lin

253 views

KU ASCO 2019 Update on Recent Developments in AML - CX-01, HuF59 Ant…

KU Hematology & Medical Oncology Review 2019

T. Lin

193 views

KU ASCO 2019 Myeloma Update: Lenalidomide vs Observation in Patients…

KU Hematology & Medical Oncology Review 2019

A. Abdallah

414 views

KU ASCO Review 2019: FDA Approval of Daratumumab in Combination with…

KU Hematology & Medical Oncology Review 2019

A. Abdallah

159 views

KU ASCO 2019 Myeloma Update: Efficacy of KRd With or Without Transpl…

KU Hematology & Medical Oncology Review 2019

A. Abdallah

109 views

KU ASCO 2019 Myeloma Update: Does Subcutaneous Daratumumab Decrease …

KU Hematology & Medical Oncology Review 2019

A. Abdallah

401 views

KU ASCO 2019: Update on CLL Preferred Therapy - BR vs Ibrutinib & Ib…

KU Hematology & Medical Oncology Review 2019

M. Hoffmann

386 views

KU ASCO 2019: Update on CLL Preferred Therapy - Venetoclax + Obinutu…

KU Hematology & Medical Oncology Review 2019

M. Hoffmann

944 views

KU ASCO 2019 Non Hodgkin Lymphoma Update : Polatuzumab Vedotin for R…

KU Hematology & Medical Oncology Review 2019

M. Hoffmann

461 views